Key Points
- Insider sale: Keros Therapeutics VP Annita Tanini sold 1,224 shares for $12,594.96 to cover tax withholding tied to vested equity awards, reducing her stake by 2.64% to 45,144 shares.
- Financial performance: Keros reported quarterly EPS of negative $1.45, missing estimates of negative $1.34, while analysts expect a full-year loss of $5.16 per share.
- Market outlook: Shares were trading near $10.95, well below the analyst consensus price target of $20.50. Ratings are mixed, with four Buy, three Hold, and two Sell recommendations.
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) VP Annita Tanini sold 1,224 shares of Keros Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $12,594.96. Following the transaction, the vice president directly owned 45,144 shares in the company, valued at approximately $464,531.76. This trade represents a 2.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Keros Therapeutics Trading Down 1.4%
KROS stock opened at $10.95 on Friday. The company has a market capitalization of $217.11 million, a P/E ratio of -2.96 and a beta of 0.99. Keros Therapeutics, Inc. has a twelve month low of $9.69 and a twelve month high of $22.55. The business has a 50 day simple moving average of $10.69 and a 200-day simple moving average of $11.85.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Research analysts predict that Keros Therapeutics, Inc. will post -5.16 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in KROS. Caitong International Asset Management Co. Ltd raised its position in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company's stock valued at $33,000 after buying an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock worth $42,000 after acquiring an additional 1,888 shares during the period. Legal & General Group Plc acquired a new position in Keros Therapeutics during the second quarter worth approximately $90,000. PDT Partners LLC acquired a new stake in shares of Keros Therapeutics during the 2nd quarter worth $122,000. Finally, Lazard Asset Management LLC purchased a new position in shares of Keros Therapeutics in the 1st quarter worth about $129,000. Institutional investors and hedge funds own 71.56% of the company's stock.
Analysts Set New Price Targets
KROS has been the topic of a number of analyst reports. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Wells Fargo & Company decreased their price target on Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 4th. Wall Street Zen cut shares of Keros Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday, August 16th. Zacks Research lowered shares of Keros Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Keros Therapeutics has an average rating of "Hold" and an average price target of $20.50.
Read Our Latest Analysis on KROS
Keros Therapeutics Company Profile
(
Get Free Report)
Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.
The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
